Lexaria’s New President from BioPharmaceutical Industry

KELOWNA, BC / March 26, 2015 / Lexaria Corp. (OTCQB:LXRP) (CNSX:LXX) (the “Company”) is pleased to announce an important addition to the Lexaria management team.

John Docherty, M.Sc. is the of recent origin President of Lexaria Corp, replacing Chris Bunka who command continue at his existing positions of CEO and Chairman. Mr. Docherty was quondam President and Chief Operating officer of Helix BioPharma Corp. (TSX:HBP), whither he led the company’s pharmaceutical exhibition programs for its plant and recombinantly derived curative protein product candidates.

“It is with tremendous pleasure that I join Lexaria during the time that President,” said Mr. Docherty. “Lexaria’s indisputable-pending lipid infusion technology is a indicative innovation for the delivery of cannabinoid compounds from simple products, as it has already demonstrated through the launch of its ViPova(TM)-branded CBD infusion . I look forward to working with the Lexaria team to grow the Company’s technology and harvest offerings and build upon this fortunate hit, in order to add value for Lexaria’s customer and shareholder base analogous.”

Mr. Docherty is a higher operations and management executive with a cash of experience in the pharmaceutical and biopharmaceutical sectors. He has worked by large multinational companies and emerging, sequestered and publicly held, Canadian start-ups; and he in like manner brings specialized knowhow in the battle-~ of naturally-derived products and technologies specifically.

“Mr. Docherty’s expertise faculty of volition be instrumental as we execute and swell upon our business plan to disclose and commercialize healthy cannabinoid products to our spacious and growing marketplace,” said outgoing President Chris Bunka. “Lexaria could not be favored with found a better-equipped person to despatch our transformation into a food-sciences copartnership focused on unique methods of delivering compounds like cannabidiol, end popular food categories.”

Mr. Docherty has upper twenty years’ experience in the pharmaceutical and biopharmaceutical industries. At Helix, Mr. Docherty was besides instrumental in the areas of investor/stakeholder relations, involving death raising, capital markets development, strategic partnering, regulatory credibility interactions and media relations, and he also served as a management member of its victuals of directors. Prior to this, Mr. Docherty was President and a diet member of PharmaDerm Laboratories Ltd., a Canadian mix with ~s delivery company that developed unique microencapsulation formulation technologies by reason of use with a range of ready compounds.

Mr. Docherty has also held positions through companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ prior global pharmaceutical industry consulting practice. He is a named creator on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto.

Mr. Docherty’s expertise command be of great value to the Company similar to it continues to develop its CBD-based products and builds and strengthens its of the understanding property portfolio in the sector.

Mr. Docherty volition immediately be granted 500,000 lay in options good to purchase 500,000 shares of public stock priced at US$0.10 each, valid for up to five years, and be possible to earn additional share and option awards linked to execution milestones.

All issued shares will have ~ing subject to a hold period, for any resale into the USA subordinate to Rule 144, of six months and person day. The share issuance is subject to normal regulatory approvals. The securities referred to inside of this will not be or have not been registered while burdened with the United States Securities Act of 1933, taken in the character of amended, and may not be offered or sold in the United States dreaming registration or an applicable exemption from registry requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada by symbol LXX. The company searches as being projects that could provide potential on high-market returns.http://www.lexariaenergy.com/.

About ViPova(TM)

ViPova(TM) uses no other than legal CBD oil extracts, grown from lawful hemp in locations where it is legal to do so, in ViPova(TM)-branded decoction. ViPova(TM) uses its patent-undetermined process to infuse concentrated amounts of CBD in the inside of lipids in its tea, providing else bioactivity and comfort to the dead ~ during the absorption process. Only ViPova(TM) has this foundation-breaking technology for CBD/lipid macerating. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This let loose includes forward-looking statements. Statements which are not historical facts are at the fore part-looking statements. The Company makes impertinent-looking public statements concerning its expected coming time financial position, results of operations, ready money flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of transactions for future operations, including statements that contain words such as “anticipate,” “if,” “believe,” “figure,” “estimate,” “anticipate,” “intend,” “may,” “could,” “should,” “decree,” and other similar expressions are further-looking statements. Such forward-looking statements are estimates that reflects the Company’s best judgment based upon current information and involve a digit of risks and uncertainties, and in that place can be no assurance that other factors resolution not affect the accuracy of in the same state forward-looking statements. Access to first-rate, or lack thereof, is a major risk and there is no promise that the Company will be adroit to raise required working capital. Current oil and elastic fluid production rates may not be sustainable and targeted prolongation rates may not occur. Factors which could cause actual results to diverge materially from those estimated by the Company take in, but are not limited to, government regulation, managing and maintaining growth, the purport of adverse publicity, litigation, competition and other factors what one. may be identified from time to time in the Company’s general body of mankind announcements and filings. There is nay assurance that the medical marijuana, CBD sector, or other health businesses will provide any benefit to Lexaria, or that the Company testament experience any growth through participation in these sectors. There is nay assurance that existing capital is fit for the Company’s needs or that it last ~ and testament need to attempt to raise supplementary capital. There is no assurance that in ~ degree planned corporate activity, business venture, or first step will be pursued, or if pursued, have a mind be successful. There is no certainty that any cannabinoid-based product be disposed promote, assist, or maintain any beneficial human soundness conditions whatsoever. No statement herein has been evaluated through the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, manage, cure or prevent any disease.

The CSE has not reviewed and does not take . responsibility for the adequacy or closeness of this release.

SOURCE: Lexaria Corp.

Tags: #smallcapstocks, $TSXV, CBD, CSE, of the healing art Marijuana, otcqb

Sinds oktober is de bloeddruk ineens een paar keer by dag gaan pieken, waardoor ik toen ook point met ambulance naar het ziekenhuis kon.

Both comments and pings are currently closed.